Figure 2.

ASO 41-1 Has Long-Lasting Activity in Brain Tissue of Human LRRK2 Transgenic Mice

(A) Immunohistochemical analysis of striatum and hippocampus from P56 LRRK2 G2019S BAC mice treated with an ASO 41-1 or non-injected at P2. Coronal sections were labeled with antibodies specific to the ASO (green) and neurons (NeuN, red), stained for nuclei (Hoechst, blue), and imaged at ×20 (left) and ×63 (right). Scale bars represent 200 μm (×20) and 50 μm (×63). (B) Immunohistochemical analysis of midbrain from the same mice as in (A). Sections were labeled with antibodies specific to ASO (green) and tyrosine hydroxylase (TH, red) and imaged at ×10 (left) and ×60 (right). Scale bars represent 200 μm (×10) and 50 μm (×60). (C) RT-PCR analysis of striatum (left), hippocampus (center), and midbrain (right) from 8-week-old WT or G2019S BAC (G2019S) mice treated at P2 with 40 μg of 2′MOE ASO targeting LRRK2 exon 41 (ASO 41-1) or non-targeted (NT ASO). Error bars are SEM. ∗∗p < 0.01, by unpaired, two-tailed t test; ∗∗∗∗p < 0.0001, one-way ANOVA with Dunnett’s MCT.